Clearmind announces publication of international patent application under PCT

Clearmind Medicine (CMND) announced the publication of an international patent application under the Patent Cooperation Treaty, PCT, as part of its ongoing collaboration with SciSparc (SPRC). The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind’s proprietary 5-methoxy-2-aminoindane and SciSparc’s Palmitoylethanolamide for the treatment of metabolic syndrome and obesity. This patent publication marks a significant milestone in the Clearmind-SciSparc collaboration, which has resulted in the filing of 13 patent families, across multiple jurisdictions, such as the United States, Europe, and China. The collaboration focuses on developing innovative therapies that combine neuroplastogens molecules with N-acylethanolamines, including PEA, to address mental health disorders such as depression and PTSD, addictions, and various metabolic conditions and obesity.